Orlando, Fla.—Adoption of infliximab biosimilars has been negligible across the United States, but Kaiser Permanente Northwest has achieved nearly full uptake of infliximab-dyyb (Inflectra, Pfizer) for both new infliximab starts and switches in three specialties that commonly use the drug.
Nationally, use of infliximab biosimilars has been growing slowly. The most recent data show that infliximab biosimilars account for only 2.4% of all infliximab infusions across the country